Get the latest news, insights, and market updates on LNTH (Lantheus Holdings, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Lantheus Holdings: Q3 Earnings Snapshot
On a per-share basis, the Bedford, Massachusetts-based company said it had net income of 41 cents. Earnings, adjusted for one-time gains and costs, were $1.27 per share. The results matched Wall Street expectations. Nov 6, 2025 - $LNTH
Lantheus Announces Leadership Transition Plan
Brian Markison to Retire as Chief Executive Officer; Board Conducting Search for Next CEO Continued Execution of Company’s Strategy to be Led by Prior CEO Mary Anne Heino as Executive Chairperson BEDFORD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Chief Executive Officer Br Nov 6, 2025 - $LNTH
Lantheus Holdings (LNTH) Valuation in Focus as Lawsuits and Pylarify Pressures Weigh on Outlook
Several law firms have launched securities class action lawsuits against Lantheus Holdings (LNTH) after the company disclosed weaker financial results, reduced sales of its flagship Pylarify product, and issued lower guidance due to competitive pressures and pricing shifts. See our latest analysis for Lantheus Holdings. Despite some promising updates for its diagnostic pipeline, recent legal and product headwinds have clearly dominated investor sentiment. Lantheus Holdings’ share price is... Nov 2, 2025 - $LNTH
Here’s Why Lantheus Holdings (LNTH) Fell in Q3
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets sustained their upward rally from April’s lows, driven by AI acceleration, reduced inflationary impacts from tariffs, and prospects for further interest rate cuts from the […] Oct 29, 2025 - $LNTH
Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease
PDUFA Date Set for August 13, 2026BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for MK-6240, the company’s investigational F18-labeled tau-targeted Positron Emission Tomography (PET) Oct 28, 2025 - $LNTH
Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time
BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025, to discuss its financial results and provide a business update for the third quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to r Oct 23, 2025 - $LNTH
Will Lantheus Holdings’ (LNTH) Pylarify Challenges Reshape Its Competitive Edge and Management Trust?
In recent months, multiple law firms announced securities class action lawsuits against Lantheus Holdings, alleging the company made misleading statements about the pricing and competitive dynamics of its oncology imaging agent, Pylarify, after disappointing sales results and lower guidance. These legal actions highlight investor concerns around transparency and disclosure, focusing particular attention on the challenges facing Lantheus’s Pylarify franchise and the company's communication... Oct 17, 2025 - $LNTH
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple